Focused On-demand Library for Transcription factor Maf

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O75444

UPID:

MAF_HUMAN

Alternative names:

Proto-oncogene c-Maf; V-maf musculoaponeurotic fibrosarcoma oncogene homolog

Alternative UPACC:

O75444; Q66I47; Q9UP93

Background:

Transcription factor Maf, also known as Proto-oncogene c-Maf, plays a pivotal role in lens fiber cell development and cellular differentiation. It regulates the expression of crystallin genes, essential for eye lens transparency and function. Additionally, it influences T-cell susceptibility to apoptosis and chondrocyte differentiation, showcasing its versatile regulatory capabilities across different tissues.

Therapeutic significance:

Given its involvement in Cataract 21 and Ayme-Gripp syndrome, both characterized by congenital cataracts and other systemic anomalies, understanding the role of Transcription factor Maf could open doors to potential therapeutic strategies. Its regulatory function in gene expression makes it a promising target for gene therapy aimed at treating or managing these complex conditions.